Microbot Medical (MBOT) has provided an announcement.
Microbot Medical Inc. has reached a significant milestone by completing the enrollment of clinical trial sites, adding the prestigious Memorial Sloan Kettering Cancer Center to its roster for the pivotal trial of the LIBERTY® Endovascular Robotic Surgical System. This achievement is a step towards the system’s anticipated FDA submission and eventual market launch. However, investors are cautioned that these forward-looking statements are not guarantees of future performance and are subject to various factors that could impact actual results.
See more data about MBOT stock on TipRanks’ Stock Analysis page.
